Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263

Article  PubMed  Google Scholar 

Tan DJH, Ng CH, Muthiah M et al (2024) Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism 152:155744

Article  CAS  PubMed  Google Scholar 

Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223–238

Article  PubMed  Google Scholar 

Kirino S, Tamaki N, Kurosaki M et al (2023) Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 53:35–42

Article  CAS  PubMed  Google Scholar 

Tamaki N, Kurosaki M, Yasui Y et al (2021) Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. Clin Infect Dis 73:e3349–e3354

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enomoto H, Akuta N, Hikita H et al (2024) Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. https://doi.org/10.1111/hepr.14047

Tamaki N, Tada T, Kurosaki M et al (2022) Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Invest New Drugs 40:1290–1297

Article  CAS  PubMed  Google Scholar 

Kirino S, Tsuchiya K, Kurosaki M et al (2020) Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE 15:e0231828

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Tsuchiya K, Kurosaki M et al (2019) Sorafenib-regorafenib sequential therapy in japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and post-regorafenib therapies in real world practice. Cancers (Basel) 11. https://doi.org/10.3390/cancers11101517

Yasui Y, Kurosaki M, Tsuchiya K et al (2022) Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study. Cancers (Basel) 14. https://doi.org/10.3390/cancers14122975

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905

Article  CAS  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1:EVIDoa2100070

Article  PubMed  Google Scholar 

Rose MG, Kennedy EB, Abou-Alfa GK et al (2024) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights. JCO Oncol Pract:Op2400189. https://doi.org/10.1200/OP.24.00189

Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78:1922–1965

PubMed  Google Scholar 

Hasegawa K, Takemura N, Yamashita T et al (2023) Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res 53:383–390

Article  PubMed  Google Scholar 

Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72:288–306

Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458

Article  CAS  PubMed  Google Scholar 

Giaj Levra M, Cotté FE, Corre R et al (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 140:99–106

Article  PubMed  Google Scholar 

Scheiner B, Roessler D, Phen S et al (2023) Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep 5:100620

Article  PubMed  Google Scholar 

Olson DJ, Eroglu Z, Brockstein B et al (2021) Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol 39:2647–2655

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402:185–195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borst J, Ahrends T, Bąbała N et al (2018) CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18:635–647

Article  CAS  PubMed  Google Scholar 

Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384

Article  CAS  PubMed  Google Scholar